FDA approves Moderna's mRNA flu vaccine after initially refusing to review it

Chronological Source Flow
Back

AI Fusion Summary

The FDA has approved Moderna's mRNA seasonal flu vaccine, mFLUSIVA, despite an initial refusal to review the application. This vaccine is intended for individuals aged 50 and older and is expected to be available for the 2026-2027 respiratory illness season. The approval follows a period where the FDA had previously declined to evaluate the product, now clearing the way for the mRNA-based seasonal flu shot to reach its target patient population in the coming years.
Community Comments
Loading updates...
0